Quadrant Capital Group’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30K | Buy |
332
+199
| +150% | +$18.3K | ﹤0.01% | 1868 |
|
|
2025
Q4 | $12K | Sell |
133
-4,635
| -97% | -$439K | ﹤0.01% | 2157 |
|
|
2025
Q3 | $470K | Buy |
+4,768
| New | +$472K | 0.02% | 910 |
|
|
2025
Q2 | – | Sell |
-4,083
| Closed | -$462K | – | 2668 |
|
|
2025
Q1 | $462K | Buy |
4,083
+3,610
| +763% | +$386K | 0.02% | 792 |
|
|
2024
Q4 | $50K | Sell |
473
-141
| -23% | -$15.1K | ﹤0.01% | 1418 |
|
|
2024
Q3 | $66.3K | Sell |
614
-301
| -33% | -$32.9K | ﹤0.01% | 1298 |
|
|
2024
Q2 | $99.3K | Buy |
915
+47
| +5% | +$5.54K | 0.01% | 1018 |
|
|
2024
Q1 | $115K | Buy |
868
+43
| +5% | +$5.37K | 0.01% | 937 |
|
|
2023
Q4 | $100K | Buy |
825
+22
| +3% | +$2.46K | 0.01% | 993 |
|
|
2023
Q3 | $90.1K | Sell |
803
-68
| -8% | -$8.63K | 0.01% | 937 |
|
|
2023
Q2 | $127K | Buy |
871
+2
| +0.2% | +$272 | 0.01% | 726 |
|
|
2023
Q1 | $112K | Buy |
869
+186
| +27% | +$23.4K | 0.01% | 761 |
|
|
2022
Q4 | $87.1K | Buy |
683
+239
| +54% | +$27.7K | 0.01% | 865 |
|
|
2022
Q3 | $46K | Sell |
444
-392
| -47% | -$43K | 0.01% | 1089 |
|
|
2022
Q2 | $88K | Sell |
836
-199
| -19% | -$23.6K | 0.01% | 674 |
|
|
2022
Q1 | $132K | Buy |
1,035
+166
| +19% | +$20K | 0.02% | 577 |
|
|
2021
Q4 | $107K | Buy |
869
+315
| +57% | +$41.2K | 0.01% | 642 |
|
|
2021
Q3 | $79K | Sell |
554
-27
| -5% | -$3.97K | 0.01% | 705 |
|
|
2021
Q2 | $91K | Buy |
581
+7
| +1% | +$1.13K | 0.01% | 642 |
|
|
2021
Q1 | $89K | Buy |
574
+65
| +13% | +$10.1K | 0.01% | 614 |
|
|
2020
Q4 | $76K | Sell |
509
-188
| -27% | -$26.6K | 0.01% | 602 |
|
|
2020
Q3 | $92K | Buy |
697
+135
| +24% | +$17.6K | 0.02% | 446 |
|
|
2020
Q2 | $65K | Sell |
562
-333
| -37% | -$38.4K | 0.01% | 625 |
|
|
2020
Q1 | $87K | Buy |
895
+48
| +6% | +$6.29K | 0.01% | 633 |
|
|
2019
Q4 | $113K | Buy |
847
+171
| +25% | +$23.6K | 0.01% | 907 |
|
|
2019
Q3 | $87K | Buy |
676
+512
| +312% | +$66.1K | 0.01% | 954 |
|
|
2019
Q2 | $17K | Sell |
164
-461
| -74% | -$54K | ﹤0.01% | 1689 |
|
|
2019
Q1 | $75K | Buy |
625
+434
| +227% | +$49.3K | 0.01% | 966 |
|
|
2018
Q4 | $17K | Buy |
191
+15
| +9% | +$1.69K | ﹤0.01% | 1242 |
|
|
2018
Q3 | $19K | Sell |
176
-128
| -42% | -$15.2K | 0.01% | 1019 |
|
|
2018
Q2 | $29K | Buy |
304
+44
| +17% | +$4.79K | 0.01% | 835 |
|
|
2018
Q1 | $23K | Buy |
260
+80
| +44% | +$9.29K | 0.01% | 910 |
|
|
2017
Q4 | $19K | Buy |
180
+17
| +10% | +$1.92K | 0.01% | 939 |
|
|
2017
Q3 | $16K | Buy |
163
+5
| +3% | +$577 | 0.01% | 1005 |
|
|
2017
Q2 | $8K | Hold |
158
| – | – | ﹤0.01% | 1191 |
|
|
2017
Q1 | $16K | Sell |
158
-38
| -19% | -$4.31K | 0.01% | 921 |
|
|
2016
Q4 | $18K | Sell |
196
-29
| -13% | -$3.11K | 0.01% | 799 |
|
|
2016
Q3 | $25K | Hold |
225
| – | – | 0.02% | 673 |
|
|
2016
Q2 | $23K | Buy |
225
+23
| +11% | +$2.6K | 0.02% | 656 |
|
|
2016
Q1 | $19K | Buy |
202
+20
| +11% | +$1.94K | 0.01% | 679 |
|
|
2015
Q4 | $17K | Hold |
182
| – | – | 0.01% | 622 |
|
|
2015
Q3 | $16K | Buy |
182
+3
| +2% | +$301 | 0.01% | 622 |
|
|
2015
Q2 | $18K | Buy |
+179
| New | +$19.8K | 0.01% | 621 |
|
Other funds holding ZBH
VCM
VPM
Quadrant Capital Group's ZBH Position: Q1 2026 in Review
Quadrant Capital Group increased its Zimmer Biomet (ZBH) stake by 150% in Q1 2026, buying an estimated $18.3K and bringing the position to 332 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.
Quadrant Capital Group first reported a position in ZBH in Q2 2015 and has held it in 43 quarters since. The position peaked at $470K in Q3 2025. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Quadrant Capital Group held 332 shares of Zimmer Biomet worth $30K as of Q1 2026.
- Quadrant Capital Group bought 199 Zimmer Biomet shares in Q1 2026, an estimated $18.3K.
- Zimmer Biomet made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1868 holding.
- Quadrant Capital Group first reported a position in Zimmer Biomet in Q2 2015 and has held it in 43 quarters since.
- Quadrant Capital Group's Zimmer Biomet position peaked at $470K in Q3 2025.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.